Skip to main content
TipRanks
Go Ultimate75% OFF

Co-Diagnostics (0A50) Stock Statistics & Valuation Metrics

0 Followers

Total Valuation

Co-Diagnostics has a market cap or net worth of $2.36M. The enterprise value is $7.56M.

Market Cap
$2.36M
Enterprise Value
$7.56M

Share Statistics

Co-Diagnostics has 10,512,190 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
10,512,190
Owned by Insiders
0.92%
Owned by Institutions
2.24%

Financial Efficiency

Co-Diagnostics’s return on equity (ROE) is -2.27 and return on invested capital (ROIC) is -138.31%.

Return on Equity (ROE)
-2.27
Return on Assets (ROA)
-1.90
Return on Invested Capital (ROIC)
-138.31%
Return on Capital Employed (ROCE)
-1.48
Revenue Per Employee
5,412.948
Profits Per Employee
-407.79K
Employee Count
115
Asset Turnover
0.03
Inventory Turnover
0.22

Valuation Ratios

The current PE Ratio of Co-Diagnostics is -0.01. Co-Diagnostics’s PEG ratio is -0.00.

PE Ratio
-0.01
PS Ratio
1.98
PB Ratio
0.15
Price to FCF
-0.06
Price to Operating Cash Flow
-0.05
PEG Ratio
-0.00

Income Statement

In the last 12 months, Co-Diagnostics had revenue of 622.49K and earned -46.90M in profits. Earnings per share was -35.25.

Revenue
622.49K
Gross Profit
400.11K
Operating Income
-31.28M
Pretax Income
-48.51M
Net Income
-46.90M
EBITDA
-47.41M
Earnings Per Share (EPS)
-35.25

Cash Flow

In the last 12 months, operating cash flow was -26.88M and capital expenditures -307,267, giving a free cash flow of -27.19M billion.

Operating Cash Flow
-26.88M
Free Cash Flow
-27.19M
Free Cash Flow per Share
-4.33

Dividends & Yields

Co-Diagnostics pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-1615.17%
Earnings Yield
-3349.00%

Stock Price Statistics

Beta
1.20
52-Week Price Change
-97.72%
50-Day Moving Average
0.81
200-Day Moving Average
2.10
Relative Strength Index (RSI)
23.58
Average Volume (3m)
57.47K

Important Dates

Co-Diagnostics upcoming earnings date is Mar 25, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 10, 2026
Next Earnings Date
Mar 25, 2027
Ex-Dividend Date
―

Financial Position

Co-Diagnostics as a current ratio of 3.87, with Debt / Equity ratio of 5.99%

Current Ratio
3.87
Quick Ratio
3.59
Debt to Market Cap
0.09
Net Debt to EBITDA
0.22
Interest Coverage Ratio
0.00

Taxes

In the past 12 months, Co-Diagnostics has paid -1.62M in taxes.

Income Tax
-1.62M
Effective Tax Rate
0.03

Enterprise Valuation

Co-Diagnostics EV to EBITDA ratio is -0.05, with an EV/FCF ratio of -0.09.

EV to Sales
2.95
EV to EBITDA
-0.05
EV to Free Cash Flow
-0.09
EV to Operating Cash Flow
-0.09

Balance Sheet

Co-Diagnostics has $714.80K in cash and marketable securities with $1.56M in debt, giving a net cash position of -$849.70K billion.

Cash & Marketable Securities
$714.80K
Total Debt
$1.56M
Net Cash
-$849.70K
Net Cash Per Share
-$0.08
Tangible Book Value Per Share
$0.35

Margins

Gross margin is -9.47%, with operating margin of -3415.85%, and net profit margin of -5527.61%.

Gross Margin
-9.47%
Operating Margin
-3415.85%
Pretax Margin
-5580.41%
Net Profit Margin
-5527.61%
EBITDA Margin
-5453.23%
EBIT Margin
-5563.51%

Analyst Forecast

The average price target for Co-Diagnostics is $4.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy

Price Target
$4.00
Price Target Upside
1654.39% Upside
Analyst Consensus
Moderate Buy
Analyst Count
1
Revenue Growth Forecast
28.89%
EPS Growth Forecast
34.53%